PetVivo Holdings, Inc. (OTCQX: PETV) announced the renaming of its subsidiary Cosmeta Corp. to Somatrix Technologies, Inc. on August 20, 2026. The move establishes a dedicated platform for human health innovation.

The rebranding reflects PetVivo’s strategy to expand its biomaterial expertise beyond its existing veterinary focus. While PetVivo Animal Health, Inc. continues to commercialize technologies for the animal market, Somatrix will concentrate on research and development for human therapeutic applications.

Strategic Expansion

Somatrix aims to develop next-generation biocompatible and functional biomaterials. These include extracellular matrix-based materials designed to interact with biological systems for tissue repair, bone remodeling, and targeted drug delivery.

John Lai, Chief Executive Officer of PetVivo Holdings, Inc., stated that the new subsidiary provides a platform to translate the company’s scientific foundation into human health innovations. He noted that these technologies may serve as platforms for multiple products across various therapeutic areas.

Therapeutic Focus Areas

The company identified several potential application areas for Somatrix’s technology portfolio:

• Musculoskeletal and joint health
• Tissue and bone repair
• Wound care
• Ocular applications
• Airway and respiratory applications
• Targeted therapeutic delivery

Certain biomaterials under development may respond to mechanical, ultrasound, or shockwave stimulation to enhance biological responses. The company believes this versatility supports a broad product pipeline addressing unmet medical needs.

Intellectual Property and Pipeline

PetVivo holds a portfolio of 12 issued and pending patents and 6 trade secrets protecting its biomaterials and production processes. Its lead product, SPRYNG with OsteoCushion technology, remains commercially available for veterinary use in cats, dogs, and horses.

Research activities within Somatrix are at various stages. Potential products will require additional testing and regulatory approval before commercialization. The company plans to provide further details as specific programs advance.

PetVivo Holdings Inc (OTCQX: PETV) reported a narrowed net loss per share of $(0.05) for the fiscal first quarter ended June 30, 2026, compared to $(0.10) in the corresponding period of the previous year. This represents a 50% improvement in losses on a per-share basis. The veterinary biomedicals provider also logged revenue of $337,572, up from $297,500 year-over-year, marking a 13.47% increase.

The company announced the acquisition of PiezoBioMembrane (PBM), an R&D partner specializing in functional biomaterials and piezoelectric technologies. Management stated the deal is subject to customary closing conditions and financing completion. PetVivo plans to pursue FDA clearance for human applications incorporating PBM’s technologies after completing safety and efficacy studies.

Financial Performance

The operating loss contracted to $1.61 million from $1.84 million in the prior year quarter. Gross profit expanded to $223,317 from $186,726, driven by higher revenues against relatively stable cost of sales which rose slightly to $114,255 from $110,774.

Total operating expenses fell to $1.83 million from $2.03 million. This reduction was primarily due to lower general and administrative expenses ($967,442 vs $1.07 million) and research and development costs ($233,419 vs $340,513). Sales and marketing expenses saw a marginal increase to $631,305 from $621,712.

Other income and expense improved significantly. The current quarter recorded only $5,039 in interest expense, whereas the prior year period included a $320,404 unrealized loss on derivative liabilities and a $149,125 loss on disposal of assets. These non-recurring items contributed to the wider net loss in the comparative period.

What the Numbers Show

The improvement in the bottom line was largely non-operational. While operating losses narrowed modestly by approximately $235,000, the year-over-year reduction in net loss is heavily influenced by the absence of significant derivative and asset disposal losses that weighed on results in the prior year. Operational efficiency gains are visible in the contraction of R&D and G&A expenses despite revenue growth.

Balance Sheet Position

Cash and cash equivalents declined to $122,633 as of June 30, 2026, from $200,782 at the end of the previous fiscal year. Total current assets stood at $941,019, down from $1.71 million, largely due to the settlement of subscriptions receivable which dropped to zero from $600,000. Inventory decreased to $451,334 from $538,366.

Total liabilities remained relatively stable at $1.31 million, with accounts payable decreasing to $453,291 from $547,421. However, notes payable and accrued interest (current portion) increased to $476,456 from $321,447. Stockholders’ equity declined to $1.36 million from $2.20 million, reflecting the accumulated deficit widening to $103.05 million.

Operational Updates

PetVivo continued the beta launch of its PetVivo.ai veterinary practice platform, claiming a 50%-90% reduction in customer acquisition costs for participating clinics. The company also advanced Stage B of its R&D program with PBM, focusing on scalable production of combined offerings for tissue regeneration. Additionally, PetVivo concluded its commercial partnership with VetStem regarding the PrecisePRP product line to focus exclusively on proprietary technologies.